Elliot M. Maza, J.D., CPA
Consulting Chief Financial Officer
Mr. Maza has served as our consulting Chief Financial Officer since December 2012 and our Chief Financial Officer since March 2007. Currently, Mr. Maza serves as Chief Executive Officer and Chief Financial Officer of BioZone Pharmaceuticals, Inc., a contract manufacturer of over-the-counter pharmaceutical and cosmetic products. From December 2003 to May 2006 Mr. Maza was Chief Financial Officer of Emisphere Technologies, Inc., a publicly held biopharmaceutical company specializing in oral drug delivery. He was a partner at Ernst and Young LLP from March 1999 to December 2003 and an investment banker at Goldman Sachs, Inc., JP Morgan Securities, Inc. and Bankers Trust Securities, Inc. at various times during April 1989 to March 1999. Mr. Maza practiced law at Sullivan and Cromwell in New York from September 1985 to April 1989. Mr. Maza received his B.A. degree from Touro College in New York and his J.D. degree from the University of Pennsylvania Law School.
Dan Shochat, Ph.D.
Consulting Vice President
Dan Shochat, Ph.D. has more than 28 years of experience in the biotechnology industry and is a pioneer in the antibody development arena. Prior to joining Intellect, he served as vice president of nonclinical development at KaloBios Therapeutics. Prior, he was among the first employees of Immunomedics Inc., Newark, NJ where he served as group director, product R&D. Dr. Shochat is the inventor of several technologies, including that of the approved in vivo tumor-imaging agent CEA-Scan; Mylotarg - the first approved antibody-cytotoxic drug conjugate; and the design, process and formulation for the commercial radiolabeling of the B1 antibody at a 55 Curie scale. The lead product from this work was Bexxar, a radioiodinated antibody for the treatment of Non-Hodgkin's Lymphoma that was approved by the FDA on June 2003. He is co-founder of Celscia Therapeutics Inc. - a therapeutic antibodies development company - which merged with KaloBios Therapeutics in January 2004.
From 2001 to 2007 Dr. Shochat was a member of the Technical Advisory Committee to the Board of Directors of the Australian Nuclear Science and Technology Organization. He also serves as consultant and member of scientific advisory boards of several biopharmaceutical companies and venture capital funds.
Dr. Shochat earned B.Sc. in Zoology and Physiology (1965) and M.Sc. in Physiology (1968) from the Hebrew University of Jerusalem, Israel and Ph.D. in Biochemistry and Protein Chemistry (1976) from LSU Medical Center, New Orleans, LA. He was a post-doctoral fellow in the Department of Biochemistry (1975-1978) and Sr. Research Associate at the Division of Experimental Pathology (1978-1983), the University of Kentucky Medical Center, Lexington, KY. In 1983 he participated in founding the Center for Molecular Medicine and Immunology at the University of Medicine and Dentistry of New Jersey, Newark, NJ, where he was an Associate Member until he joint Immunomedics, Inc. in 1984. From 1986-1992 Dr. Shochat served successively as visiting lecturer and adjunct professor at the Chemistry Department of Rutgers University Graduate School (Newark, NJ campus).